Genmab A/S (OTCMKTS:GNMSF – Get Free Report)’s share price reached a new 52-week low during mid-day trading on Monday . The company traded as low as $190.15 and last traded at $190.15, with a volume of 717 shares changing hands. The stock had previously closed at $197.44.
Genmab A/S Stock Performance
The stock’s fifty day simple moving average is $209.38 and its two-hundred day simple moving average is $233.81. The company has a market cap of $12.76 billion, a price-to-earnings ratio of 18.57 and a beta of 1.04.
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Stories
- Five stocks we like better than Genmab A/S
- The Significance of Brokerage Rankings in Stock Selection
- 3 Must-Have ETFs Set to Dominate This Quarter
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Seeking Stability? These 3 Stocks Offer Strong Potential
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Trade War Bargain Stocks: Top 3 Picks Too Good to Pass Up
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
